Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)

BACKGROUND: S-1, an oral fluoropyrimidine, plus cisplatin (SP) is a standard regimen for advanced gastric cancer (AGC) in East Asia. To date, no studies have evaluated the efficacy and safety of trastuzumab combined with SP in patients with human epidermal growth factor receptor type 2 (HER2)-positi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kurokawa, Y, Sugimoto, N, Miwa, H, Tsuda, M, Nishina, S, Okuda, H, Imamura, H, Gamoh, M, Sakai, D, Shimokawa, T, Komatsu, Y, Doki, Y, Tsujinaka, T, Furukawa, H
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2014
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3950868/
https://ncbi.nlm.nih.gov/pubmed/24473399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.18
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados